Table 2.
Head to head comparisons between different β blockers (reported as point estimates of odds ratios or weighted mean differences with 95% credible intervals, with number of studies contributing to network)
| Agent | Odds ratio | Change in LVEF (%) (secondary outcome) (n=10) (weighted mean difference) | |||
|---|---|---|---|---|---|
| Death (primary outcome) (n=21) | Cardiovascular death (secondary outcome) (n=13) | Sudden death (secondary outcome) (n=12) | Drug discontinuation (secondary outcome) (n=21) | ||
| Any β blocker versus placebo/standard treatment: | |||||
| Standard pair-wise frequentist analysis | 0.71 (0.64 to 0.80) | 0.76 (0.70 to 0.84) | 0.73 (0.61 to 0.88) | 0.88 (0.78 to 0.98) | 4.2% (3.1% to 4.9%) |
| Bayesian analysis | 0.69 (0.56 to 0.80) | 0.71 (0.49 to 0.95) | 0.70 (0.49 to 0.92) | 1.12 (0.99 to 1.31) | 4.1% (3.4% to 4.8%) |
| Atenolol versus: | |||||
| Placebo/standard treatment | 0.53 (0.15 to 1.83) | 0.64 (0.11 to 3.60) | 0.41 (0.05 to 2.82) | 0.75 (0.39 to 1.41) | NA |
| Bisoprolol | 0.83 (0.22 to 2.94) | 0.90 (0.12 to 6.42) | 0.64 (0.06 to 5.16) | 0.80 (0.39 to 1.61) | NA |
| Bucindolol | 0.62 (0.16 to 2.22) | 0.79 (0.10 to 6.05) | 0.49 (0.05 to 4.44) | 0.59 (0.18 to 1.85) | NA |
| Carvedilol | 0.95 (0.25 to 3.33) | 1.30 (0.19 to 8.85) | 0.73 (0.09 to 6.36) | 0.91 (0.46 to 1.79) | NA |
| Metoprolol | 0.76 (0.20 to 2.70) | 0.76 (0.09 to 5.31) | 0.46 (0.05 to 4.09) | 0.89 (0.45 to 1.75) | NA |
| Nebivolol | 0.62 (0.16 to 2.27) | 0.74 (0.09 to 5.15) | 0.68 (0.06 to 6.96) | 0.72 (0.35 to 1.51) | NA |
| Bisoprolol versus: | |||||
| Placebo/standard treatment | 0.65 (0.47 to 0.89) | 0.70 (0.28 to 1.79) | 0.65 (0.25 to 1.84) | 0.94 (0.70 to 1.20) | NA |
| Bucindolol | 0.74 (0.44 to 1.27) | 0.86 (0.22 to 3.59) | 0.76 (0.19 to 3.63) | 0.75 (0.26 to 1.96) | NA |
| Carvedilol | 1.15 (0.79 to 1.69) | 1.42 (0.46 to 4.85) | 1.10 (0.40 to 5.16) | 1.15 (0.83 to 1.54) | NA |
| Metoprolol | 0.93 (0.61 to 1.39) | 0.84 (0.20 to 3.06) | 0.73 (0.18 to 3.29) | 1.12 (0.77 to 1.56) | NA |
| Nebivolol | 0.76 (0.44 to 1.23) | 0.83 (0.21 to 3.10) | 1.07 (0.21 to 5.93) | 0.91 (0.61 to 1.41) | NA |
| Bucindolol versus: | |||||
| Placebo/standard treatment | 0.87 (0.57 to 1.28) | 0.82 (0.28 to 2.23) | 0.86 (0.28 to 2.43) | 1.26 (0.50 to 3.40) | 4.5% (4.1% to 4.8%) |
| Carvedilol | 1.53 (0.98 to 2.43) | 1.65 (0.47 to 6.11) | 1.46 (0.44 to 6.49) | 1.54 (0.59 to 4.17) | 0.3% ( to 3.7% to 4.2%) |
| Metoprolol | 1.23 (0.76 to 2.04) | 0.98 (0.21 to 3.78) | 0.96 (0.19 to 4.26) | 1.51 (0.57 to 4.16) | 0.9% (−2.8% to 4.6%) |
| Nebivolol | 1.02 (0.56 to 1.75) | 0.96 (0.21 to 3.78) | 1.42 (0.24 to 7.46) | 1.22 (0.46 to 3.57) | 2.0% (−2.0% to 5.9%) |
| Carvedilol versus: | |||||
| Placebo/standard treatment | 0.56 (0.44 to 0.71) | 0.49 (0.22 to 0.97) | 0.58 (0.21 to 1.11) | 0.83 (0.67 to 0.99) | 4.2% (2.0% to 6.4%) |
| Metoprolol | 0.80 (0.59 to 1.08) | 0.59 (0.20 to 1.39) | 0.67 (0.19 to 1.49) | 0.99 (0.75 to 1.23) | 0.6% (−2.1% to 3.4%) |
| Nebivolol | 0.66 (0.39 to 1.02) | 0.58 (0.16 to 1.80) | 0.97 (0.17 to 3.71) | 0.79 (0.56 to 1.20) | 1.7% (−1.1% to 4.5%) |
| Metoprolol versus: | |||||
| Placebo/standard treatment | 0.71 (0.53 to 0.92) | 0.84 (0.32 to 2.41) | 0.90 (0.31 to 2.59) | 0.84 (0.67 to 1.06) | 3.6% (1.9% to 5.2%) |
| Nebivolol | 0.82 (0.49 to 1.32) | 0.98 (0.25 to 4.06) | 0.68 (0.27 to 8.25) | 0.80 (0.57 to 1.28) | 1.1% (−1.7% to 3.8%) |
| Nebivolol versus placebo/standard treatment | 0.78 (0.43 to 1.33) | 0.85 (0.33 to 2.32) | 0.61 (0.16 to 2.29) | 1.04 (0.71 to 1.38) | 2.5% (0.3% to 4.7%) |
LVEF=left ventricular ejection fraction; NA=not available or applicable or reported.